Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376380 | 1.00 | ALDH1A1 (0.46) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL21110979 | 0.87 | ALDH1A1 (0.51) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL15415376 | 0.84 | ALDH1A1 (0.44) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL2218560 | 0.82 | HSD11B1 (0.45) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL6365338 | 0.82 | USP30 (0.48) | CTSLCTSBCTSKKMT2AMEN1 | |
| SCHEMBL6361575 | 0.82 | USP30 (0.48) | CTSLCTSBCTSKKMT2AMEN1 | |
| SCHEMBL29232309 | 0.80 | ALDH1A1 (0.53) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL23043429 | 0.80 | ABCB1 (0.41) | ALDH1A1CTSLCTSBCTSKKMT2A | |
| SCHEMBL27223224 | 0.80 | ABCB1 (0.41) | ALDH1A1CTSLCTSBCTSKKMT2A | |
| SCHEMBL704571 | 0.80 | ABCB1 (0.41) | ALDH1A1CTSLCTSBCTSKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043408-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-02-08 | — | — | US | disclosed |
| EP-4190775-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | Transthera Sciences (Nanjing), Inc. (CN) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022022735-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | 药捷安康(南京)科技股份有限公司 | 2022-02-03 | — | — | WO | disclosed |
| EP-3508482-B1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) | 2020-12-16 | — | — | EP | disclosed |
| US-10744139-B2 | Inhibitors of fibroblast growth factor receptor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-08-18 | — | — | US | disclosed |
| US-20200108070-A2 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-04-09 | — | — | US | disclosed |
| US-20190209564-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-3508482-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2019-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744139-B2 | Inhibitors of fibroblast growth factor receptor and use thereof | FGFR1, FGFR2, FGFR3 | ALDH1A1 298/4885GAA 2592/4885CTSL 4393/4885 |
| US-20240043408-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | FGF2, FGFR1, FGF1 | ALDH1A1 1880/4885GAA 1036/4885CTSL 156/4885 |
| US-20200108070-A2 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | FGFR1, FGFR2, FGFR3 | ALDH1A1 298/4885GAA 2592/4885CTSL 4393/4885 |
| US-20190209564-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | FGFR1, FGFR2, FGFR3 | ALDH1A1 298/4885GAA 2592/4885CTSL 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.